LANXESS Stock Forecast for 2023 - 2025 - 2030
Updated on 03/29/2024
LANXESS Stock Forecast and Price Target
The average price target for LANXESS's stock lately set by several renowned analysts is 26.00€, which would result in a potential upside of approximately 6.82% if it reaches this mark by December 31, 2024. This estimation is based on a high estimate of 42.00€ and a low estimate of 21.00€. If you're interested in LXS stock, looking at its competitors might also be a good idea.
6.82% Upside
LANXESS Fair Value Forecast for 2023 - 2025 - 2030
LANXESS's Price has decreased In the last four years, from 47.32€ to 0.00€ – a 100.00% drop. For next year, the 16 analysts predict Fair Value of 19.60€, which would mean an increase of 100.00%. Over the next seven years, the pros' prediction is Fair Valueof 47.30€, which would mean a seven-year growth forecast of 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$734.37 | Buy/Sell | $636.99 | 10.71% |
XOM Stock Forecast | Exxon Mobil Corp | Outperform |
4
|
$109.02 | Buy/Sell | $124.27 | 12.23% |
JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$161.23 | Buy/Sell | $174.55 | 5.44% |
MRK Stock Forecast | Merck | Outperform |
2
|
$122.77 | Buy/Sell | $130.51 | 9.96% |
TMO Stock Forecast | Thermo Fisher Scientific | Outperform |
10
|
$599.43 | Buy/Sell | $591.94 | 0.10% |
LANXESS Revenue Forecast for 2023 - 2025 - 2030
In the last two years, LANXESS's Revenue has grown, increasing from 6.10€B to 8.09€B – an increase of 32.50%. In the following year, 17 experts forecast LANXESS's Revenue will decrease by 8.73%, to 7.38€B. Over the next seven years, the pros' prediction is Revenueof 8.82€B, which would mean a seven-year growth forecast of 9.04%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
RELIANCE Stock Forecast | Reliance Industries | Outperform |
10
|
Rp2.93k | Buy/Sell | Rp2.77k | 2.45% |
AZN Stock Forecast | AstraZeneca PLC | Outperform |
17
|
£104.50 | Buy/Sell | £165.99 | 53.79% |
NOVN Stock Forecast | Novartis | Outperform |
10
|
CHF88.80 | Buy/Sell | CHF105.00 | 23.95% |
LANXESS Dividend per Share Forecast for 2023 - 2025 - 2030
LANXESS's Dividend per Share has increased by 5.00% In the last two years, going from 1.00€ to 1.05€. According to 15 major analysts, LANXESS's Dividend per Share will fall by 13.33% in the next year, reaching 0.91€. For the next seven years, the forecast is for Dividend per Share to grow by 1.05%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
PFE Stock Forecast | Pfizer | Outperform |
2
|
$28.37 | Buy/Sell | $32.87 | 10.82% |
AMGN Stock Forecast | Amgen | Outperform |
4
|
$275.36 | Buy/Sell | $303.65 | 14.40% |
HON Stock Forecast | Honeywell International Inc | Outperform |
12
|
$200.29 | Buy/Sell | $219.12 | 11.34% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$54.36 | Buy/Sell | $58.15 | 1.18% |
GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$75.32 | Buy/Sell | $87.82 | 10.20% |
SHW Stock Forecast | Sherwin Williams | Outperform |
15
|
$340.39 | Buy/Sell | $317.38 | -0.19% |
LANXESS EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, LANXESS's EBITDA has grown by 9.06%, from 784.00€M to 855.00€M. According to 14 analysts, LANXESS's EBITDA will fall by 12.94% in the next year, reaching 744.37€M. Over the next seven years, experts predict that EBITDA will grow by 7.70%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
GSK Stock Forecast | GSK | Outperform |
12
|
£16.75 | Buy/Sell | £17.30 | 11.04% |
ECL Stock Forecast | Ecolab | Hold |
18
|
$223.90 | Buy/Sell | $205.36 | 1.38% |
2010 Stock Forecast | Saudi Basic Industries | Hold |
10
|
﷼78.70 | Buy/Sell | ﷼96.26 | 17.28% |
LANXESS EBIT Forecast for 2023 - 2025 - 2030
In the last two years, LANXESS's EBIT has grown from 376.00€M to 377.00€M – a 0.27% increase. In the following year, 12 experts forecast that LANXESS's EBIT will decrease by 46.86%, to 200.35€M. Over the next seven years, the forecast is for EBIT to grow by 79.31%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
MMM Stock Forecast | 3M | Hold |
10
|
$94.05 | Buy/Sell | $109.39 | 15.90% |
BAS Stock Forecast | BASF | Outperform |
12
|
49.06€ | Buy/Sell | 49.50€ | 4.97% |
GIVN Stock Forecast | Givaudan | Hold |
14
|
CHF3.94k | Buy/Sell | CHF3.14k | -16.22% |
LANXESS EPS Price Prediction Forecast for 2023 - 2025 - 2030
LANXESS's EPS has decreased In the last four years, from 3.50€ to 0.00€ – a 100.00% drop. For next year, the 16 analysts predict EPS of 1.45€, which would mean an increase of 100.00%. Over the next seven years, the pros' prediction is EPSof 3.50€, which would mean a seven-year growth forecast of 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
DOW Stock Forecast | Dow | Hold |
2
|
$57.43 | Buy/Sell | $57.75 | -2.49% |
CTVA Stock Forecast | Corteva | Outperform |
12
|
$55.09 | Buy/Sell | $61.72 | 14.36% |
600309 Stock Forecast | Wanhua Chemical Group | Buy |
16
|
¥77.42 | Buy/Sell | ¥106.85 | 39.50% |